Batoprotafib

N/A

Report date: 2026/03/13 20:02:36
NME

Base Information

Drug NameBatoprotafib
Drug Alias NameTNO-155
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNon-receptor protein tyrosine phosphatases antagonistsSrc homology phosphotyrosyl phosphatase 2 inhibitors
TargetsNon-receptor protein tyrosine phosphatasesSrc homology phosphotyrosyl phosphatase 2
Therapy Area/IndicationsSolid tumoursRenal InsufficiencyHepatic Insufficiency +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[19] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Ag
Inactive CompaniesChina Novartis Institutes For Biomedical Research Co Ltd
Active IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[5] 
Inactive IndicationsRenal InsufficiencyHepatic InsufficiencySquamous Cell Carcinoma of Head and Neck +[7] 

Other Information

ATC CodeN/A
Related LinksN/A